Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing

Human Pathology: Case Reports

Volumn 1, Issue 2, 2014, Pages 21-28

  Harms, Paul W ^a   Hristov, Alexandra C ^a   Kim, David S ^b   Anens, Tobenna ^c   Quist, Michael J ^d   Siddiqui, Javed ^a   Carskadon, Shannon ^a   Mehra, Rohit ^a   Fullen, Douglas R ^a   Johnson, Timothy M ^a   Chinnaiyan, Arul M ^a   Palanisamy, Nallasivam ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MARSHFIELD CLINIC   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

EZH2; Lymphoma; Melanoma; sequencing; Transcriptome

Indexed keywords

B RAF KINASE; CD19 ANTIGEN; CD20 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN LAMBDA CHAIN; MELAN A; MONOCLONAL ANTIBODY HMB 45; PROTEIN BCL 2; PROTEIN S 100; RITUXIMAB; TRANSCRIPTION FACTOR EZH2;

ADULT; ARTICLE; CARCINOGENESIS; CASE REPORT; CUTANEOUS MELANOMA; EPIGENETIC REPRESSION; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; METASTATIC MELANOMA; NEXT GENERATION SEQUENCING; NRAS GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

EID: 84921981974     PISSN: None     EISSN: 22143300     Source Type: Journal    
DOI: 10.1016/j.ehpc.2014.07.002     Document Type: Article

References (30)

1. Dunki-Jacobs EM, Callender GG, McMasters KM. Current management of melanoma. Curr Probl Surg 2013;50:351-82.
2. Tentori L, Lacal PM, Graziani G. Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol Sci 2013;34:656-66.
3. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in BRAFmutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61-8.
4. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4:94-109.
5. Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst 2014; 106:djt435.
6. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485:502-6.
7. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191-6.
8. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012;44:133-9.
9. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
10. Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal. Mol Cancer Res 2014;12:639-53.
11. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, et al.Genetic and epigenetic loss ofmicroRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012;3:1011-25.
12. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73.
13. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
14. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar- Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
15. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
16. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011;117:2451-9.
17. Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS. Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation. Oncogene 2014 [Electronically published Jan 27, 2014].
18. Hodis E,Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-63.
19. McCabeMT,OttHM,GanjiG,Korenchuk S, Thompson C,VanAller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphomawith EZH2-activating mutations. Nature 2012;492:108-12.
20. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009;106: 12353-8.
21. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009;458:97-101.
22. Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, et al. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn 2013;15:790-5.
23. Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011;6:e28585.
24. Wong CW, Fan YS, Chan TL, Chan AS, Ho LC, Ma TK, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005;58:640-4.
25. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D, et al. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 2013;341:240-7.
26. Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC, et al. EZH2- dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res 2011;9:418-29.
27. Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz- Wagenblatt A, et al. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 2013;133:768-75.
28. McHugh JB, Fullen DR, Ma L, Kleer CG, Su LD. Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol 2007;34:597-600.
29. West DS, Dogan A, Quint PS, Tricker-Klar ML, Porcher JC, Ketterling RP, et al. Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. Am J Surg Pathol 2013;37:978-86.
30. Stoecker MM, Wang E. Histiocytic/dendritic cell transformation of B-cell neoplasms: pathologic evidence of lineage conversion in differentiated hematolymphoid malignancies. Arch Pathol Lab Med 2013;137:865-70.